Clinical Trial Update: Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment [Phase 2]

View source ↗

Summary

Phase 2 study results evaluate safety and efficacy of ADS-5102 (amantadine extended-release) in people with multiple sclerosis and walking impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ADS-5102 (amantadine)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Walking Impairment, Multiple Sclerosis | Phase 2 | Status: COMPLETED